BIOXCEL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm
Investors have until September 5, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Investors have until September 5, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- On December 15, 2021, the Company announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease.
- The Company announced that the program consisted of two randomized, double-blind, placebo-controlled studies: TRANQUILITY II and TRANQUILITY III.
- BioXcel further disclosed that the fabricated email correspondence was provided to the FDA during an on-site inspection in December 2022.